Lipid Lowering Agents Deck 2

Question 1

Hypertriglyceridemia normal

Answer 1

Normal – <150 mg/dL

Question 2

Hypertriglyceridemia mild

Answer 2

Mild hypertriglyceridemia – 150 to

499 mg/dL

Question 3

Hypertriglyceridemia Moderate

Answer 3

Moderate hypertriglyceridemia – 500 to

886 mg/dL

Question 4

Hypertriglyceridemia very high

Answer 4

Very high or severe hypertriglyceridemia –

>886 mg/dL

Question 5

Hypertriglyceridemia indications

Answer 5

• Indications for drug therapy
– Prevention of pancreatitis mg/dL
• TG levels persistently above 886 – start drug
therapy
• TG > 500 with prior episode of pancreatitis –
consider drug therapy
– CV disease risk reduction

Question 6

Hypertriglyceridemia start with a

Answer 6

fibrate (typically fenofibrate

rather than gemfibrozil)

Question 7

Hypertriglyceridemia managment

Answer 7

• Fish oil – those that contain

eicosapentaenoic acid/docosahexaenoic acid concentrate

Question 8

–fish oil can Reduce VLDL production and can lower

serum TG by as much as

Answer 8

s 50% or more

Question 9

fish oil use often limited by

Answer 9

metabolic and GI side

effects

Question 10

PCSK Inhibitors approved treatment

Answer 10

• Approved treatment of individuals with

inadequately treated levels of LDL-C

Question 11

PCSK Inhibitors

can lower

Answer 11

Can lower LDL-C as much as 60% in patients on

statin therapy

Question 12

PCSK Inhibitors

reduction in rates

Answer 12

Reductions in rates of stroke or MI

Question 13

PCSK Inhibitors

moa

Answer 13

PCSK9 binds to the low density lipoprotein
receptor on the surface of hepatocytes, leading to
the degradation of the LDL-R and higher plasma LDL-C levels.

Question 14

PCSK Inhibitors

atniboides to

Answer 14

ntibodies to PCSK9 interfere with its binding of the

LDL-R leading to higher hepatic LDL-R expression and lower plasma LDL-C levels